Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 13Terminated 4Recruiting 4Unknown 2Active not recruiting 2Withdrawn 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 17Carcinoma, Non-Small-Cell Lung 13Squamous Cell Carcinoma of Head and Neck 7Lung Neoplasms 5Colorectal Neoplasms 5Neoplasm Metastasis 4Head and Neck Neoplasms 4Neoplasms 3Multiple Myeloma 3Lymphoma 3Leukemia, Myeloid, Acute 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Sarcoma 2Myelodysplastic Syndromes 2Lymphoma, B-Cell 2Hematologic Neoplasms 2Esophageal Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Adenocarcinoma 2Xeroderma Pigmentosum 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Resectable Non-Small Cell Lung Cancer 1

Interventions

Dexamethasone 14Rituximab 6Cytarabine 5venetoclax 4Lenalidomide 4Bortezomib 4Bendamustine Hydrochloride 4selinexor 3pomalidomide 3pembrolizumab 3ibrutinib 3fludarabine 3carfilzomib 3Paclitaxel 3Gemcitabine 3Drug Therapy 3Cyclophosphamide 3Calcium Dobesilate 3ixazomib 2gilteritinib 2fludarabine phosphate 2elotuzumab 2daratumumab 2belinostat 2Tablets 2Surveys and Questionnaires 2Panobinostat 2Oxaliplatin 2Granulocyte Colony-Stimulating Factor 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Recurrence × Nivolumab × Clear all
NCT02962804 2018-03-05

Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)

University of Kansas Medical Center

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡